Baird lowered the firm’s price target on Tandem Diabetes (TNDM) to $33 from $37 and keeps a Neutral rating on the shares. The firm updated its model following its Q4 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Sell Rating for Tandem Diabetes Care Due to Revenue Shortfalls and High Valuation
- Tandem Diabetes price target lowered to $58 from $63 at Canaccord
- Tandem Diabetes Care: FDA Approval and Strategic Growth Opportunities Drive Buy Rating
- Tandem Diabetes Care Reports Record 2024 Sales Growth
- Tandem Diabetes Care: Strong International Sales and Promising 2025 Outlook Justify Buy Rating